by ADRIAN MANZ | Aug 20, 2025 | The Doctor's Dose
Target CEO Change Overshadows Earnings: What Day Traders Should Watch Target posted a slight Q2 beat, but price action says the leadership shift is the real catalyst. Here’s how to trade the reaction—because in the short term, Target CEO change overshadows earnings....
by ADRIAN MANZ | Aug 20, 2025 | The Doctor's Dose
Meme Stock Pump-and-Dump Scams: A Day Trader’s Survival Guide In July, a fresh wave of meme-stock “ramps” rocketed thinly traded microcaps before collapsing just as fast—leaving billions in paper wealth erased and a trail of retail accounts blown up. Here’s what...
by ADRIAN MANZ | Aug 20, 2025 | The Doctor's Dose
Advance Auto Parts (AAP) After Earnings: A Deeper Dive and Day-Trading Playbook Advance Auto Parts posted an EPS beat but guided 2025 lower as interest expense rises following a $1.95B notes offering. The stock’s third straight double-digit post-earnings move makes...
by ADRIAN MANZ | Aug 19, 2025 | The Doctor's Dose
Oracle’s AI Rally Pauses: A Deeper Dive with Day-Trading Setups Oracle (ORCL) slipped more than 4% to ~238 after a torrid June–July run that peaked at 260.87. Price is now decisively below the 21-day moving average while still hovering a few percent above the 50-day,...
by ADRIAN MANZ | Aug 19, 2025 | The Doctor's Dose
Merck Keytruda Medicare Delay: What It Means for Day Traders The recent tweak to Medicare’s drug price negotiation program has given Merck (MRK) a brief lifeline. While long-term investors are debating whether the change truly softens the looming Keytruda patent...
by ADRIAN MANZ | Aug 19, 2025 | The Doctor's Dose
A Tweak to Medicare is Good for Merck. But Can It Revive the Stock? Merck & Co. has found a small reprieve in Washington, but investors remain skeptical that it will meaningfully alter the company’s trajectory. A new tweak to Medicare’s drug price negotiation...
by ADRIAN MANZ | Aug 19, 2025 | The Doctor's Dose
September Fed Rate Cut: Why Day Traders Should Prepare for a Hawkish Surprise Fed expectations vs. market reality The S&P 500, currently hovering above 6400, has rallied on expectations of a September Fed rate cut. Fed funds futures are pricing an 85% chance of a...
by ADRIAN MANZ | Aug 18, 2025 | The Doctor's Dose
Intel Government Stake Talks and Day Trading Implications The Trump administration is reportedly considering a 10% equity stake in Intel (INTC), which would convert billions in CHIPS Act funding into ownership. The proposal underscores Washington’s deepening...
by ADRIAN MANZ | Aug 18, 2025 | The Doctor's Dose
Retail Earnings, Tariffs, and Day Trading: Where the Real Risk Lies Why this week matters Headline numbers may look fine; the risk is guidance as retailers speak to the back half (B2S and holiday). Tariff pass-through is the swing factor: modest so far, but price...
by ADRIAN MANZ | Aug 18, 2025 | The Doctor's Dose
Novo Nordisk Wegovy MASH approval: Why NVO is jumping—and how day traders can trade it Quick take Novo Nordisk shares pop after the FDA grants accelerated approval for Wegovy to treat MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis in...
